A study of several treatments for new and returning glioblastoma
Official title: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study looks at more than one treatment for a brain tumor called glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Key facts
- Registry number
- NCT03970447
- Stage of testing
- Phase 2/Phase 3
- Conditions studied
- Glioblastoma
Where it is running
This trial lists 63 sites.
-
Alabama
- University of Alabama at Birmingham (Birmingham)
-
California
- University of California, San Diego (La Jolla)
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute (Los Angeles)
- University of California, Los Angeles (Los Angeles)
- St. Joseph Hospital (Orange)
- University of California, San Francisco (San Francisco)
- Stanford Cancer Center (Stanford)
-
Canton of Vaud
- Centre Hospitalier Universitaire Vaudois Lausanne (Lausanne)
-
Colorado
- University of Colorado Denver (Aurora)
-
Connecticut
- Yale Cancer Center / Smilow Cancer Hospital* (New Haven)
-
Florida
- Mayo Clinic Cancer Center (Jacksonville)
- Sylvester Comprehensive Cancer Center* (Miami)
- Moffitt Cancer Center (Tampa)
-
France
- Centre Hospitalier Lyon Sud / Hôpital Neurologique P. Wertheimer (Bron)
- Hopital de la Timone (Marseille)
- Hopital Piti-Salpetriere (Paris)
-
Georgia
- Piedmont Atlanta Hospital (Atlanta)
- Winship Cancer Institute of Emory University (Atlanta)
-
Germany
- Uniklinik Koeln - Zentrum fuer Neurologie und Psychiatrie (Cologne)
- Dr. Senckenbergisches Institut für Neuroonkologie (Frankfurt)
- Universitätsklinik Heidelberg (Heidelberg)
- Universitaetsklinikum Heidelberg - Neurologische Klinik (Mannheim)
- Universitätsklinikum Regensburg (Regensburg)
- Universitätsklinikum Tübingen (Tübingen)
-
Louisiana
- LSU Health Sciences Center - New Orleans (New Orleans)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
-
Michigan
- Henry Ford Health System (Detroit)
-
Minnesota
- Allina Health Systems/Abbott Northwestern Hospital (Minneapolis)
- Mayo Clinic Cancer Center - Rochester (Rochester)
-
Mississippi
- University of Mississippi Medical Center (Jackson)
-
Missouri
- Washington University School of Medicine - Siteman Cancer Center (St Louis)
-
New South Wales
- Northern Sydney Cancer Centre/Royal North Shore Hospital (St Leonards)
- Calvary Mater Newcastle (Waratah)
-
New York
- Perlmutter Cancer Center, NYU Langone Health (New York)
- Icahn School of Medicine at Mount Sinai (New York)
- Columbia University Medical Center (New York)
- Memorial Sloan Kettering Cancer Center* (New York)
-
North Carolina
- Duke University Medical Center (Durham)
- Comprehensive Cancer Center of Wake Forest* (Winston-Salem)
-
Ohio
- University Hospitals Cleveland Medical Center* (Cleveland)
- Cleveland Clinic (Cleveland)
- Ohio State University Cancer Center (Columbus)
-
Ontario
- Sunnybrook Health Sciences Centre (Toronto)
- Princess Margaret Cancer Centre (Toronto)
-
Pennsylvania
- University of Pennsylvania - Perelman Center for Advanced Medicine (Philadelphia)
- Allegheny General Hospital (Pittsburgh)
- University of Pittsburgh Medical Center - Hillman Cancer Center (Pittsburgh)
-
Quebec
- Montreal Neurological Institute and Hospital, McGill University (Montreal)
- Université de Sherbrooke (Sherbrooke)
-
Queensland
- Royal Brisbane and Women's Hospital (Herston)
-
South Australia
- Flinders Medical Centre (Bedford Park)
-
South Carolina
- Medical University of South Carolina - Hollings Cancer Center (Charleston)
-
Switzerland
- University Hospital Zurich (Zurich)
-
Texas
- Texas Oncology - Austin (Austin)
- University of Texas Southwestern Medical Center (Dallas)
- University of Texas - MD Anderson Cancer Center (Houston)
-
Utah
- University of Utah - Huntsman Cancer Institute (Salt Lake City)
-
Victoria
- Austin Health (Heidelberg)
- Peter MacCallum Cancer Centre (Melbourne)
-
Virginia
- University of Virginia Health (Charlottesville)
-
Washington
- University of Washington Medical Center (Seattle)
-
Wisconsin
- Froedtert Hospital/Medical College of Wisconsin (Milwaukee)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.